Kala pharmaceuticals stock news
Webb6 apr. 2024 · Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment Dec. 30, 2024 at 12:02 p.m. ET by Tomi Kilgore Kala climbs 81% … Webb14 apr. 2024 · Some better-ranked stocks for investors interested in the same sector are CRISPR Therapeutics CRSP, Kala Pharmaceuticals KALA and Allogene Therapeutics ALLO, each carrying a Zacks Rank #2 (Buy) at ...
Kala pharmaceuticals stock news
Did you know?
WebbAsset Growth. -37.73%. Trailing 12-Months. The Kala Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating … Webb4 mars 2024 · Kala Pharmaceuticals, Inc. (KALA) Latest Stock News & Headlines - Yahoo Finance Dow 30 Kala Pharmaceuticals, Inc. (KALA) NasdaqCM - NasdaqCM … Get breaking news stories and in-depth coverage with videos and photos. The …
Webb19 maj 2024 · On January 19, 2024, Kala Pharmaceuticals, Inc., a Delaware corporation (the "Company"), entered into an Open Market Sale AgreementSM (the "Sales Agreement") with Jefferies LLC, as agent ("Jefferies"), pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share (the "Common … Webb11 apr. 2024 · Kala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of …
Webb6 apr. 2024 · Kala Pharmaceuticals, Inc. Common Stock (KALA) Stock Price, Quote, News & History Nasdaq MY QUOTES: KALA Edit my quotes Kala Pharmaceuticals, … Webb6 apr. 2024 · Kala Pharmaceuticals Inc (KALA) NASDAQ: KALA Stock Analysis Analyst Forecasts Technical Analysis Chart Earnings Dividends Financials News & Insights Insider Trading Crowd Wisdom Hedge Funds Similar Stocks Risk Analysis Kala Pharmaceuticals (KALA) Stock News & Sentiment 1,422 Followers Portfolio
Webb12 apr. 2024 · Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect. ARLINGTON, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and …
Webb12 apr. 2024 · The trading price of Kala Pharmaceuticals Inc. (NASDAQ:KALA) floating higher at last check on Wednesday, April 12, closing at $17.86, 4.81% higher than its … plhrwmh eforiasWebb31 mars 2024 · Kala Pharmaceuticals stock falls 13% as Q4 net loss widens, revenue declines Y/Y SA News Tue, Mar. 29, 2024 Kala Pharmaceuticals GAAP EPS of -$0.68 misses by $0.29, revenue of $1.87M misses by $1.55M plhrothta fragmatvnWebb15 nov. 2024 · Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface ... plhroforikh me efarmogew sth bioiatrikhWebb12 apr. 2024 · April 12, 2024 - 8:00 am. ARLINGTON, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, … plhrwmh oteWebb14 apr. 2024 · Kala Pharmaceuticals (NASDAQ:KALA – Get Rating) had its target price lifted by equities research analysts at HC Wainwright from $20.00 to $22.00 in a research note issued on Wednesday, The Fly reports.The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 23.32% from the … princess arrowsWebb10 apr. 2024 · Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye … princess arsinoeWebb4 jan. 2024 · View the latest Kala Pharmaceuticals Inc. (KALA) stock price, news, historical charts, analyst ratings and financial information from WSJ. plhrwmh cosmote